文献速递肾移植

联合血基因表达与供体cfDNA诊断肾移植亚临床排斥

Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-01-01

该研究对208例肾移植受者的428份样本进行回顾性分析,评估血基因表达谱与供体来源cfDNA单独或联合诊断亚临床排斥的性能。联合检测的AUC为0.81,显著高于单独基因表达谱(P<0.001)或cfDNA(P=0.006);基因表达谱更擅长检测细胞性排斥,cfDNA更擅长检测抗体介导性排斥。

要点

  • 联合血基因表达谱与供体cfDNA可提高亚临床排斥无创诊断效能。
  • 基因表达谱对细胞性排斥诊断更优,cfDNA对抗体介导性排斥更优。
  • 双阴性时阴性预测值达88%,双阳性时阳性预测值达81%。

核心结论

  • 联合血基因表达谱与供体cfDNA可提高亚临床排斥的检测效能并提供更无创的监测。

研究设计与样本

  • 对观察性临床试验CTOT-08中208例受试者的428份样本进行事后分析,同步检测血基因表达谱与供体cfDNA并与监测活检配对。

主要发现

  • 基因表达谱诊断亚临床排斥的阴性预测值82%、阳性预测值47%、平衡准确度64%、AUC 0.75。
  • 供体cfDNA诊断亚临床排斥的阴性预测值84%、阳性预测值56%、平衡准确度68%、AUC 0.72。
  • 双阴性时阴性预测值升至88%,双阳性时阳性预测值升至81%。
  • 联合多变量逻辑回归的AUC为0.81,显著高于单独基因表达谱(P<0.001)或单独cfDNA(P=0.006)。
  • 基因表达谱检测细胞性排斥的AUC为0.80,优于cfDNA的0.62(P=0.001);cfDNA检测抗体介导性排斥的AUC为0.84,优于基因表达谱的0.71(P=0.003)。

临床怎么用

  • 可联合血基因表达谱与供体cfDNA对稳定期肾移植受者进行无创筛查,减少监测活检。
  • 根据疑似排斥类型侧重解读:细胞性排斥优先参考基因表达谱,抗体介导性排斥优先参考cfDNA。
  • 双阴性结果可提高排除亚临床排斥的可靠性,双阳性结果可提高确诊信心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Subclinical acute rejection is associated with poor outcomes in kidney transplant recipients. As an alternative to surveillance biopsies, noninvasive screening has been established with a blood gene expression profile. Donor-derived cellfree DNA (cfDNA) has been used to detect rejection in patients with allograft dysfunction but not tested extensively in stable patients. We hypothesized that we could complement noninvasive diagnostic performance for subclinical rejection by combining a donor-derived cfDNA and a gene expression profile assay. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a post hoc analysis of simultaneous blood gene expression profile and donor-derived cfDNA assays in 428 samples paired with surveillance biopsies from 208 subjects enrolled in an observational clinical trial (Clinical Trials in Organ Transplantation-08). Assay results were analyzed as binary variables, and then, their continuous scores were combined using logistic regression. The performance of each assay alone and in combination was compared. RESULTS: For diagnosing subclinical rejection, the gene expression profile demonstrated a negative predictive value of 82%, a positive predictive value of 47%, a balanced accuracy of 64%, and an area under the receiver operating curve of 0.75. The donor-derived cfDNA assay showed similar negative predictive value (84%), positive predictive value (56%), balanced accuracy (68%), and area under the receiver operating curve (0.72). When both assays were negative, negative predictive value increased to 88%. When both assays were positive, positive predictive value increased to 81%. Combining assays using multivariable logistic regression, area under the receiver operating curve was 0.81, significantly higher than the gene expression profile (P<0.001) or donor-derived cfDNA alone (P=0.006). Notably, when cases were separated on the basis of rejection type, the gene expression profile was significantly better at detecting cellular rejection (area under the receiver operating curve, 0.80 versus 0.62; P=0.001), whereas the donor-derived cfDNA was significantly better at detecting antibody-mediated rejection (area under the receiver operating curve, 0.84 versus 0.71; P=0.003). CONCLUSIONS: A combination of blood-based biomarkers can improve detection and provide less invasive monitoring for subclinical rejection. In this study, the gene expression profile detected more cellular rejection, whereas donor-derived cfDNA detected more antibody-mediated rejection.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Park S, Guo K, Heilman RL, et al. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2021. PMID: 34620649. doi:10.2215/CJN.05530421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。